Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction
- 1 November 1989
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 61 (03) , 497-501
- https://doi.org/10.1055/s-0038-1646622
Abstract
Pharmacokinetics and systemic effects of recombinant tissue type plasminogen activator (rt-PA) were determined during coronary thrombolysis in 12 acute myocardial infarction patients using a consecutive intravenous infusion regimen. Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean ±SD) of 3310±950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of. 2210±470 nglml and 930±200 ng/ml, respectively. All patients received intravenous heparin. Total clearance of rt-PA was 380±74 ml/min, t,½α was 3.6±0.9 min and t,½β was 16±5.4 min. After 90 min, in plasma samples containing anti-rt-PA-IgG to inhibit in vitro effects, fibrinogen was decreased to 54%, plasminogen to 52%, α2-antiplasmin to 25%, α2-macroglobulin to 90% and antithrombin III to 85% of initial values. Coagulation times were prolonged and fibrin D-dimer concentrations increased from 0.40 to 2.7 μg/ml. It is concluded that pharmacokinetics of rt-PA show low interpatient variability and that its short mean residence time in plasma allows precise control of therapy. Apart from its moderate effect on the haemostatic system, rt-PA appears to lyse a fibrin pool in addition to the coronary thrombus.Keywords
This publication has 11 references indexed in Scilit:
- 190 Dose linearity and differentiation of in vitro and in vivo effects of RT-PA on haemostatic parameters in healthy menFibrinolysis, 1988
- Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybridsFibrinolysis, 1988
- Neue Methoden zur spezifischen Bestimmung von Fibrinspaltprodukten (D-Dimere)Journal of Laboratory Medicine, 1988
- Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarctionJournal of the American College of Cardiology, 1987
- Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosisThe American Journal of Cardiology, 1986
- Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation.Circulation, 1986
- Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.Circulation, 1986
- Statistical estimations in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1974
- A Rapid, Simple, Sensitive Method for Measuring Fibrinolytic Split Products in Human SerumExperimental Biology and Medicine, 1969
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957